JP Morgan Healthcare Conference

Transcription

1 JP Morgan Healthcare Conference Giovanni Caforio Chief Operating Officer January 13, 2015

2 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This presentation also contains certain non-gaap financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-gaap financial measures to the most comparable GAAP measures are available on the company s website at 2 2

3 Our Strategic Foundation Best of BIOTECH Best of PHARMA Diversified Specialty BioPharma INNOVATE INTEGRATE IMPROVE People helping patients in their fight against serious disease 3

4 Keys to Delivering Future Growth Realize potential of key products Advance a diverse and innovative pipeline Leverage the specialty care model Pursue disciplined capital allocation Leverage business development 4

5 Our Commercial Priorities Drive Brand Performance Focus on Prioritized Markets Accelerate Innovation 5

6 Our Key Products & Compounds Daklinza & Sunvepra approved in Japan; Daklinza approved in Europe; 2 Opdivo approved in US, Japan 6

7 Unique and differentiated profile with broad label Investing to drive growth and become the leading global NOAC Continued strong performance with accelerating trends 7

8 Realizing the Transformational Potential of I-O First to offer melanoma patients the possibility of long-term survival Continued strong brand performance Recent US approval in advanced metastatic melanoma Additional global regulatory submissions 8

9 Realizing the Transformational Potential of I-O Positive results from Phase 3 study in lung cancer CheckMate -017 stopped early for efficacy Broad clinical trial program ongoing for Opdivo and Yervoy Monotherapy and combination regimens Exploring more than 20 tumor types Registrational studies ongoing in 7 tumors Early stage clinical assets Urelumab (anti-cd137), Lirilumab (anti-kir), anti LAG-3 Monotherapy and combination regimens in broad range of tumors Preclinical Aggressive plans for additional assets into the clinic over the next months 9

10 Our R&D Focus Disease Area Focus Drug Platforms Immuno-Oncology Oncology Immunoscience Cardiovascular Small Molecules Biologics Virology Fibrotic Diseases Genetically Defined Diseases Antibody Drug Conjugates Millamolecules 10

11 Capital Allocation: A Balanced Approach Continue to be in a solid financial position: Strong balance sheet Business development remains a top priority Dividend commitment 6 th consecutive annual increase 11

12 Business Development: Core to Our Strategy Licensing Acquisition Partnerships Strategically, Scientifically & Financially Aligned 12

13 Confident in Our Future Commercial performance of key/new brands Innovative pipeline to fuel long-term growth Continued evolution of specialty model Disciplined capital allocation Positioned for long-term success 13 13

14 JP Morgan Healthcare Conference Giovanni Caforio Chief Operating Officer January 13,